Edition:
India

Adaptimmune Therapeutics PLC (ADAP.OQ)

ADAP.OQ on NASDAQ Stock Exchange Global Select Market

8.10USD
11:41pm IST
Change (% chg)

$-0.28 (-3.28%)
Prev Close
$8.38
Open
$8.45
Day's High
$8.66
Day's Low
$8.06
Volume
54,982
Avg. Vol
73,517
52-wk High
$9.22
52-wk Low
$3.76

Select another date:

Thu, Nov 2 2017

BRIEF-Adaptimmune Therapeutics Q3 loss per share $0.00

* Adaptimmune reports third quarter 2017 financial results and business updates

BRIEF-Matrix Capital reports 12.9 pct passive stake in Adaptimmune Therapeutics

* Matrix Capital Management Company Lp reports 12.9 percent passive stake in Adaptimmune Therapeutics Plc as of August 31, 2017 - SEC filing Source text: (http://bit.ly/2wSEc1U)

GSK bets on pioneering cancer therapy with Adaptimmune deal

LONDON GlaxoSmithKline said it has licensed the rights to Adaptimmune's pioneering T-cell therapy program to boost its pipeline in oncology, one of four areas its has prioritized for research and development.

BRIEF-GSK exercises option over SPEAR T-cell therapy program targeting NY-ESO

* Adaptimmune Therapeutics Plc - ‍GSK exercises option over SPEAR T-cell therapy program targeting NY-ESO​

Select another date: